The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

Journal of Medical Economics
Adam LloydGergana Zlateva

Abstract

To evaluate the cost-effectiveness of pregabalin in the treatment of fibromyalgia in a US patient population. A decision-analytic model was developed comparing pregabalin 150 mg twice a day (BID) and pregabalin 225 mg BID to placebo, duloxetine, gabapentin, tramadol, milnacipran, and amitriptyline in patients with severe fibromyalgia (Fibromyalgia Impact Questionnaire score >59; pain score >6.5). The model estimated response rates for all treatments at 12 weeks based on three randomized trials with pregabalin and a systematic review of published randomized controlled trials. Response was categorized as ≥30% improvement in baseline pain score plus global impression of change rating of much improved or very much improved. After 12 weeks of treatment, responders to treatment entered a treatment Markov model in which response was maintained, lost, or treatment discontinued. The cost-effectiveness end-points were cost per responder at 12 weeks and 1 year. Resource use was estimated from published studies and costs were estimated from the societal perspective. Over 12 weeks, total cost per patient was $229 higher with pregabalin 150 mg BID than placebo, whereas pregabalin 225 mg BID was $866 less costly than placebo. At 1 year, prega...Continue Reading

References

Jan 1, 1995·Arthritis and Rheumatism·F WolfeL Hebert
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Oct 13, 2000·Journal of General Internal Medicine·P G O'MalleyJ L Jackson
Nov 18, 2004·JAMA : the Journal of the American Medical Association·Don L GoldenbergLeslie Crofford
Apr 9, 2005·Arthritis and Rheumatism·Leslie J CroffordUNKNOWN Pregabalin 1008-105 Study Group
Jun 7, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Peter T WeirJoseph L Lyon
Nov 30, 2006·Pain Practice : the Official Journal of World Institute of Pain·Mugdha GoreDouglas L Leslie
Jul 24, 2007·Annals of the Rheumatic Diseases·S F CarvilleUNKNOWN EULAR
Jul 28, 2007·International Journal of Clinical Practice·A BergerG Oster
Nov 22, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lesley M ArnoldUma Sharma
Jan 12, 2008·Journal of Occupational and Environmental Medicine·Leigh Ann WhiteRebecca L Robinson
Jun 6, 2008·The Journal of Pain : Official Journal of the American Pain Society·Lesley M ArnoldGeorge Haig
Jul 22, 2008·Patient Education and Counseling·Lesley M ArnoldSusan A Martin
Oct 1, 2000·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·A NiizawaK Terasawa
Oct 1, 2000·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·I J RussellW A Katz
Apr 3, 2009·Cleveland Clinic Journal of Medicine·Lauren KimAtul Deodhar
Apr 17, 2009·The Journal of Rheumatology·Robert M BennettAlesia B Sadosky
Feb 25, 2010·Current Medical Research and Opinion·Ernest ChoyGergana Zlateva
Apr 10, 2010·BMC Musculoskeletal Disorders·Stuart SilvermanGergana Zlateva
Apr 27, 2010·The Journal of Pain : Official Journal of the American Pain Society·Winfried HäuserClaudia Sommer
Nov 9, 2010·Journal of Clinical Pharmacy and Therapeutics·T G TzellosD Kouvelas
Aug 27, 2011·Seminars in Arthritis and Rheumatism·Ernest ChoyHelen A Dakin

❮ Previous
Next ❯

Citations

Mar 18, 2016·Pain Management·Milena De Felice, Michael H Ossipov
May 13, 2014·Pain Practice : the Official Journal of World Institute of Pain·Lindsay ParkerJoaquin Mould
Jan 1, 2012·Scientifica·Michael H Ossipov
Oct 16, 2018·PloS One·Margreet S H WortmanTim C Olde Hartman
Feb 26, 2013·Archives of Pharmacal Research·Ankesh KukkarAmteshwar Singh Jaggi
Jul 20, 2019·Current Pharmaceutical Biotechnology·Insa BackhausGiuseppe La Torre

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.